WAVE Life Sciences (NASDAQ:WVE) Given New $35.00 Price Target at Wedbush

WAVE Life Sciences (NASDAQ:WVE) had its target price boosted by Wedbush from $33.00 to $35.00 in a report published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other analysts have also recently commented on WVE. Truist Financial increased their price target on shares of WAVE Life Sciences from $36.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Citigroup increased their price objective on WAVE Life Sciences from $16.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen cut WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Morgan Stanley set a $28.00 target price on WAVE Life Sciences in a research report on Monday, December 8th. Finally, UBS Group set a $32.00 price target on WAVE Life Sciences in a research note on Tuesday, December 16th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, WAVE Life Sciences has an average rating of “Moderate Buy” and an average price target of $33.13.

WAVE Life Sciences Trading Down 0.6%

NASDAQ WVE opened at $13.12 on Friday. WAVE Life Sciences has a 1-year low of $5.28 and a 1-year high of $21.73. The company has a 50 day moving average of $14.00 and a 200-day moving average of $10.94. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -10.75 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The business had revenue of $17.25 million for the quarter, compared to the consensus estimate of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, analysts forecast that WAVE Life Sciences will post -1.14 earnings per share for the current year.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, major shareholder Plc Gsk bought 1,470,000 shares of the stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the acquisition, the insider owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christian O. Henry sold 93,445 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $14.65, for a total value of $1,368,969.25. Following the completion of the transaction, the director directly owned 12,700 shares in the company, valued at approximately $186,055. This trade represents a 88.04% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 948,375 shares of company stock valued at $14,112,151. 23.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On WAVE Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in WVE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in WAVE Life Sciences by 9.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock worth $463,000 after buying an additional 4,957 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of WAVE Life Sciences by 3.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock valued at $4,506,000 after acquiring an additional 20,624 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of WAVE Life Sciences by 8.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company’s stock valued at $188,000 after acquiring an additional 2,206 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of WAVE Life Sciences by 93.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,097 shares of the company’s stock valued at $235,000 after acquiring an additional 17,424 shares during the period. Finally, Compass Rose Asset Management LP bought a new position in WAVE Life Sciences during the 2nd quarter worth approximately $650,000. Institutional investors own 89.73% of the company’s stock.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wedbush raised its price target on WVE to $35 and reiterated an “outperform” rating — a bullish signal implying substantial upside versus the current price and likely supporting buy-side interest. Wedbush price target raise
• Positive Sentiment: HC Wainwright increased near-term EPS estimates across Q1–Q4 2026 and kept a “Buy” rating with a $30 target, signaling improving analyst sentiment on WAVE’s financial outlook. (Research note summarized in market coverage.)
• Positive Sentiment: Wave announced acceptance of a late‑breaking oral presentation for WVE‑006 (GalNAc‑RNA editing) at the American Thoracic Society conference — new data from the RestorAATion‑2 trial (400 mg multidose and 600 mg single‑dose cohorts) will be presented, which could materially move the stock depending on the clinical readout. ATS presentation acceptance
• Neutral Sentiment: Analysts’ long‑range earnings expectations were updated in a report setting FY2029 estimates — useful for modeling but unlikely to drive immediate price moves absent near‑term catalysts. Analyst expectations for FY2029
• Negative Sentiment: A CNBC piece highlighted recent FDA reversals and heightened regulatory scrutiny across biotech (citing multiple denials and reversals), which has increased sector volatility and likely weighed on WVE shares despite company‑specific positives — investors are more sensitive to regulatory risk today. FDA reversals raise sector concerns

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.